KR20150141943A - 장 손상 및 밀착연접 기능장애 관련 질병의 치료 및 예방을 위한 방법 및 조성물 - Google Patents

장 손상 및 밀착연접 기능장애 관련 질병의 치료 및 예방을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20150141943A
KR20150141943A KR1020157025637A KR20157025637A KR20150141943A KR 20150141943 A KR20150141943 A KR 20150141943A KR 1020157025637 A KR1020157025637 A KR 1020157025637A KR 20157025637 A KR20157025637 A KR 20157025637A KR 20150141943 A KR20150141943 A KR 20150141943A
Authority
KR
South Korea
Prior art keywords
glycerophosphate
subject
composition
exercise
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157025637A
Other languages
English (en)
Korean (ko)
Inventor
알란 이. 크리거만
마가렛 티. 웨이즈
Original Assignee
프렐리프 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프렐리프 인코포레이티드. filed Critical 프렐리프 인코포레이티드.
Publication of KR20150141943A publication Critical patent/KR20150141943A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
KR1020157025637A 2013-02-20 2014-02-20 장 손상 및 밀착연접 기능장애 관련 질병의 치료 및 예방을 위한 방법 및 조성물 Withdrawn KR20150141943A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361766976P 2013-02-20 2013-02-20
US61/766,976 2013-02-20
US201361827080P 2013-05-24 2013-05-24
US61/827,080 2013-05-24
US201361897672P 2013-10-30 2013-10-30
US61/897,672 2013-10-30
PCT/US2014/017408 WO2014130678A2 (en) 2013-02-20 2014-02-20 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction

Publications (1)

Publication Number Publication Date
KR20150141943A true KR20150141943A (ko) 2015-12-21

Family

ID=50240015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157025637A Withdrawn KR20150141943A (ko) 2013-02-20 2014-02-20 장 손상 및 밀착연접 기능장애 관련 질병의 치료 및 예방을 위한 방법 및 조성물

Country Status (9)

Country Link
US (1) US20150374725A1 (https=)
EP (1) EP2958567A2 (https=)
JP (1) JP2016509059A (https=)
KR (1) KR20150141943A (https=)
CN (1) CN105163740A (https=)
AU (1) AU2014218903A1 (https=)
HK (1) HK1219868A1 (https=)
MX (1) MX2015010765A (https=)
WO (1) WO2014130678A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US5665415A (en) 1995-07-26 1997-09-09 Akpharma Inc. Composition and method for increasing the pH of acid foods
US20020099037A1 (en) * 2001-01-19 2002-07-25 Akpharma, Inc. Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts
US7402323B2 (en) 2002-08-21 2008-07-22 Akpharma, Inc. Compositions and methods for treating skin conditions
US20070155664A1 (en) * 2003-07-04 2007-07-05 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2008100980A1 (en) * 2007-02-14 2008-08-21 Prelief Inc. Methods for treating or preventing inflammation using a glycerophosphate salt
US20080220084A1 (en) * 2007-03-09 2008-09-11 Pfantastic Medical Research Institute, Llc Combination therapy for alleviating pain-related conditions
EP2180895A4 (en) * 2007-08-30 2012-04-11 Prelief Inc METHODS FOR IMPROVING THE HEALING OF ORAL INJURY USING GLYCEROPHOSPHATE SALT
WO2009052489A2 (en) * 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening

Also Published As

Publication number Publication date
WO2014130678A2 (en) 2014-08-28
EP2958567A2 (en) 2015-12-30
MX2015010765A (es) 2016-05-09
WO2014130678A3 (en) 2014-11-20
AU2014218903A1 (en) 2015-09-17
CN105163740A (zh) 2015-12-16
US20150374725A1 (en) 2015-12-31
JP2016509059A (ja) 2016-03-24
HK1219868A1 (zh) 2017-04-21

Similar Documents

Publication Publication Date Title
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
JP5468015B2 (ja) 抗菌ペプチド系に対する作動薬
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
KR20190015609A (ko) 당뇨병 치료를 위한 조성물 및 치료법
IL273955B2 (en) Delayed release deferiprone tablets and methods of using the same
MX2014000517A (es) Composiciones de nicotinamida y el uso terapeutico de las mismas.
JP5049139B2 (ja) 内臓痛を治療するためのオキシコドンの使用
MX2008005936A (es) Composiciones para regular trastornos metabolicos y metodos de uso de las mismas.
ES2995086T3 (en) Gastrointestinal health composition
KR20150141943A (ko) 장 손상 및 밀착연접 기능장애 관련 질병의 치료 및 예방을 위한 방법 및 조성물
US20070078111A1 (en) LPA2 receptor agonist inhibitors of CFTR
ES2906316T3 (es) Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas
JP4950903B2 (ja) ボンベシン／ガストリン放出ペプチドアンタゴニストの、炎症性状態、急性肺損傷及び双極性障害の治療のための使用
US20060122275A1 (en) Agentfor reducing side effects of diclofenac
TW202416948A (zh) 用於治療發炎之組合療法
WO2010017403A2 (en) Therapeutic compositions, devices and methods for observing treated tissues
EP3870175A1 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
Davis Novel Analgesics and the Impact of Route of Administration in the Horse
Özgüney Conventional and novel pharmaceutical dosage forms on prevention of gastric ulcers
CN118903067A (zh) 治疗肥胖症的方法
TW202416945A (zh) 用於治療發炎之組合療法
EA040171B1 (ru) Фармацевтическая композиция для лечения ожирения и сопутствующих ему нарушений и способ ее получения
HK40030435A (en) Delayed release deferiprone tablets and methods of using the same
HK40030435B (en) Delayed release deferiprone tablets and methods of using the same
Van Zyl The role of p-glycoprotein and peptides in attention deficit disorder with hyperactivity (ADHD)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid